Background: While phototherapy is a well-established treatment for many dermatoses, data from the literature regarding its use in elderly patients are quite limited. oBjective: In this study, we aimed to determine the phototherapy indications in geriatric patients and to evaluate the effectiveness and reliability of phototherapy in this group. Methods: This study included 95 patients of 65 years of age and older who were treated in our phototherapy unit between 2006 and 2015. The data for this study were collected retrospectively from patient follow-up forms in the phototherapy unit. results: Phototherapy was administered to 28 (29.5%) patients for mycosis fungoides, 25 (26.3%) patients foplaque type psoriasis, 12 (12.6%) patients for palmoplantar psoriasis, 12 (12.6%) patients for generalized pruritus, and 18 (19%) for other dermatoses. Of the patients, 64.2% had received a narrowband UVB (NB-UVB), 21.1% oral psoralen UVA (PUVA), and 14.7% local PUVA treatment. A complete response was achieved in 76.9-85.7% of the mycosis fungoides and in 73.71-100% of the psoriasis vulgaris patients treated with NB-UVB and PUVA, respectively. All the patients with generalized pruritus were treated with NB-UVB, and 80% of these patients achieved significant improvement. The erythema rate was found to be 0.43% per session for NB-UVB treatment and 0.46% per session for PUVA treatment as a side effect. study liMitations: The limitations of our study are that it was retrospective and the remission durations of the patients are not known. conclusion: This study showed that phototherapy is effective and reliable in the elderly population with proper dose increases and close follow-up.
INTRODUCTION
Nowadays, there is an increase in the geriatric population in both developed and developing countries. According to 2014 data, 8 .3% of the world population is older than 65 years of age, and this ratio is 8% in Turkey. 1 When observed demographically, this change causes important health problems and makes it mandatory to arrange healthcare services accordingly. In addition to systemic disorders, dermatologic diseases are also important in terms of affecting the quality of life in this age group. 2 Being aware of the metabolic and physiological changes with age and considering the accompanying comorbidities and drug use in these patients are important in terms of preventing iatrogenic complications when selecting the treatment method. 3 Although topical treatments can also be used for some dermatologic disorders in order to prevent the side effects of systemic treatments, phototherapy becomes an important treatment choice in cases where topical treatments are ineffective. Phototherapy is a treatment method with proven effectiveness and reliability in the adult age group, but the data in the literature regarding its use in the elderly population are inadequate.
The present study aimed to determine the phototherapy indications in patients of 65 years of age and older, who were followed up in our phototherapy unit between 2006 and 2015, and to evaluate the efficacy and safety of phototherapy in commonly seen dermatoses in this age group.
METHODS
This study included 95 patients of 65 years of age and older, who were followed up in our phototherapy unit between 2006 and 2015. The phototherapy data were evaluated retrospectively from the follow-up forms of the phototherapy unit.
Phototherapy Protocol
Narrowband UVB (NB-UVB) treatment and oral psoralen UVA (PUVA) were administered with the Daavlin Spectra 305/350 model UV device to the patients included in the study. All treatment protocols were started at three times a week. NB-UVB treatment was started with 70% of the minimal erythema dose (MED), and PUVA treatment was started with 70% of the minimal phototoxic dose (MPD). The subsequent dosage increased by 10-20% of the previous dose at each session, according to the clinical situation of the patient for NB-UVB. 8-methoxypsoralen was administered at a dose of 0.6mg/kg for PUVA, and treatment was continued with 0.5 j increases weekly. Treatment was continued with 10% increases in the case of minimal erythema presence during the treatment with NB-UVB. The dose was not increased in the case of continuous moderate erythema.
The treatment was interrupted until symptoms regressed in the cases of severe erythema, edema and bullae development. After symptoms regressed, treatment was continued with 50% of the last dose, and dose increases were determined as 10%. Treatment was continued without an increase in PUVA treatment in the case of the presence of minimal-mild erythema. The treatment was interrupted until symptoms regressed in the cases of severe erythema, edema, and bullae development. After symptoms regressed, treatment was started with 50% of the last dose and continued with 10% increases.
Patients who used only topical corticosteroids, moisturizers, or antihistamines were included in the study. Patients who were treated with phototherapy for less than 8 sessions (due to their own request)
were excluded from the evaluation of the relationship between the disorder and the phototherapy dose, effects, and side effects. Improvement of more than 75% in the initial lesion for the other dermatoses and complete improvements in the symptom of itching according to the feedback of the patient were accepted as recovery.
The treatment was continued until total remission was obtained or no additional improvement was seen in the following sessions.
Statistical Analysis
The analysis of the data was performed using the SPSS for 
Generalized Pruritus (n=12)
Generalized pruritus was present in 12.6% of the patients 
Lichen Planus (n=8)
All the patients with lichen planus received NB-UVB treatment, and a response was achieved in 37.5% of the patients, with a median cumulative dose of 21.4 (4.9-99.7) j/cm 2 and a median number of 19 (9-60) sessions. graph 1: Distribution of patients based on therapy received 
Side Effects
The photosensitive drugs that the patients most often used are summarized in table 5 
DISCUSSION
This study demonstrated that phototherapy is effective and reliable in the elderly population. Studies evaluating skin disorders and quality of life in the elderly population are available in the literature, but, to date, only one study has evaluated the use of phototherapy in this population. 4 Powell et al. reported that psoriasis was the most common skin disorder, with 51% of 37 elderly patients treated with phototherapy, while in the present study mycosis fungoides (29.5%) was the disorder treated most frequently with phototherapy in the elderly. 4 Mycosis fungoides is mainly observed after 55-60 years of age, and phototherapy is included among the first-step treatments for early stage mycosis fungoides (stage 1A, 1B, 2A). [5] [6] Therefore, this result is not unexpected. 8 On the other hand, they pointed out that retinoid treatment was given in addition to phototherapy in 53.7%, corticosteroid treatment in 3.2%, and methotrexate treatment in 2.1% of the patients included in their study. 9 In another study, 64% of the patients with mycosis fungoides treated with PUVA achieved a complete response, with an average of 19.5 (7-50) sessions. 9 The response rate with NB-UVB in mycosis fungoides cases varies between 54% and 91% in other studies, and the number of sessions for full recovery with NB-UVB is reported to be between 19 and 36. 7 In our study, a complete response was observed in 85.7%
of the patients with mycosis fungoides who were treated with NB-UVB, with a median number of 55 sessions and a cumulative dose of Pruritus is a common dermatologic problem in the elderly population with a prevalence of 29% and is usually idiopathic in this age group. 13 There is a scarcity of publications on phototherapy in generalized pruritus. [14] [15] [16] 12 Martin et al. reported that an acute adverse event was observed in 0.6% of NB-UVB treatments and 1.3% of systemic PUVA treatments in their study where they evaluated the acute side effects of these two methods. 20 In our study, the incidence of erythema per treatment was 0.43% for NB-UVB treatment and 0.46% for PUVA treatment. No side effect, except slightly elevated liver enzymes secondary to psoralen, which would require the interruption of treatment, was found in any of the patients treated with PUVA. No difference was observed between the two treatment groups in terms of side effects. However, the low number of patients and the fact that PUVA treatment was not used in the risky patient group may have caused this result. Late side effects of phototherapy such as photoaging and photocarcinogenicity, were not evaluated in our patients.
The limitations of our study are that it was retrospective and that the remission durations of the patients are unknown. However, this study is valuable as the number of patients is high, and there are no other studies in the literature that evaluate the number of phototherapy sessions, dose, effectiveness, and side effects of phototherapy together in the elderly population.
CONCLUSION
In conclusion, the incidence of the response rate and adverse effects in our study is consistent with results from other studies in the literature, and our data shows that phototherapy is effective and reliable with proper dose increases and close follow-up in geriatric patients. q 
